Mid-Atlantic Section of the American Urological Association
Home | About Us | Contact Us   
  Home
  Members
    Members Only Area
    Member Directory
    Join the MA-AUA
  Annual Meeting
  Board of Directors
  Committees
  Careers
  Newsletters
  Visit the AUA
  Advocacy Efforts
  MAAUA Research
  Scholarship
Didusch Museum
About the Mid-Atlantic Section of the American Urological Association (MAAUA)

 
  Members Only
  Username
 
  Password
 
   Forgot Password?

 

 

Pathologic Characteristics of Repeat Prostate Biopsy After Initial Negative Biopsy

Jeremy Weiss*, Phillip C Ginsberg, Michael J Metro, Richard C Harkaway
Albert Einstein Medical Center, Philadelphia, PA

Objectives. To review the pathological characteristics of positive prostate biopsies after one or negative or suspicious biopsies in order to improve counseling and ameliorate patient apprehension prior to repeat biopsy
Methods. Between January 1996 and December 2004, 1735 prostate biopsies were performed at a single institution. 158 people had more than one biopsy session. We compared the biopsy sets that were initially negative or suspicious with the subsequent biopsies. Data was compiled regarding repeat biopsy result, number of positive cores, laterality and Gleason score.
Results. Of the 163 biopsy sets compared, 75% (123/163) remained negative or suspicious after an initial negative or suspicious biopsy with a median time between biopsy sessions of 22.5 months. The remaining 40 biopsies that converted to positive had a median number of 1.7 positive cores, as well as unilateral disease found in 87.5% of specimens with an average Gleason score of 6.5.
Conclusions. In counseling patients prior to repeat biopsy, most likely the pathology will not be positive. If it is positive, the patient is more likely to have low volume, unilateral, low-grade disease that is suggestive of organ confined and potentially curable cancer.

Back to Final Program

 

 

Copyright © 2012 Mid-Atlantic Section of the American Urological Association. All Rights Reserved.
Read Privacy Policy.